Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
6
75%
Ph phase_3
2
25%

Phase Distribution

0

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
6(75.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(3)

Detailed Status

Completed5
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (75.0%)
Phase 32 (25.0%)

Trials by Status

terminated113%
completed563%
withdrawn225%

Recent Activity

0 active trials
Showing 5 of 8
withdrawnphase_2

Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence

NCT03566290
withdrawnphase_2

Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence

NCT03508648
completedphase_2

GTx-024 as a Treatment for Stress Urinary Incontinence in Women

NCT02658448
completedphase_2

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

NCT02463032
terminatedphase_2

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

NCT02368691
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03566290Phase 2

Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence

Withdrawn
NCT03508648Phase 2

Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence

Withdrawn
NCT02658448Phase 2

GTx-024 as a Treatment for Stress Urinary Incontinence in Women

Completed
NCT02463032Phase 2

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

Completed
NCT02368691Phase 2

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Terminated
NCT01355497Phase 3

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Completed
NCT01355484Phase 3

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT00467844Phase 2

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8